GSK plc (NYSE:GSK) Receives $43.25 Consensus PT from Analysts

GSK plc (NYSE:GSK) has earned a consensus rating of “Moderate Buy” from the ten research firms that are currently covering the firm, Marketbeat reports. Seven analysts have rated the stock with a hold rating and three have issued a strong buy rating on the company. The average 1 year price target among brokers that have covered the stock in the last year is $43.25.

GSK has been the topic of several recent research reports. Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and decreased their price target for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Guggenheim lowered shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Argus upgraded shares of GSK to a “strong-buy” rating in a research report on Wednesday, August 7th. Finally, Barclays upgraded shares of GSK to a “hold” rating in a research report on Tuesday, August 27th.

Insider Buying and Selling at GSK

In related news, major shareholder Plc Gsk bought 2,791,930 shares of the firm’s stock in a transaction on Friday, September 27th. The stock was bought at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the purchase, the insider now directly owns 16,775,691 shares of the company’s stock, valued at approximately $134,205,528. This represents a 19.97 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 10.00% of the company’s stock.

Institutional Investors Weigh In On GSK

Several institutional investors and hedge funds have recently modified their holdings of the business. FMR LLC lifted its stake in shares of GSK by 8.3% in the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after purchasing an additional 2,224,345 shares during the last quarter. Fisher Asset Management LLC lifted its stake in shares of GSK by 4.9% in the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after purchasing an additional 870,449 shares during the last quarter. Primecap Management Co. CA lifted its stake in shares of GSK by 2.4% in the 3rd quarter. Primecap Management Co. CA now owns 14,853,755 shares of the pharmaceutical company’s stock valued at $607,222,000 after purchasing an additional 342,365 shares during the last quarter. Provident Trust Co. lifted its stake in shares of GSK by 1.7% in the 3rd quarter. Provident Trust Co. now owns 3,953,602 shares of the pharmaceutical company’s stock valued at $161,623,000 after purchasing an additional 66,765 shares during the last quarter. Finally, Hotchkis & Wiley Capital Management LLC lifted its stake in shares of GSK by 30.8% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock valued at $144,803,000 after purchasing an additional 833,080 shares during the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Price Performance

NYSE GSK opened at $33.96 on Monday. GSK has a 12 month low of $32.83 and a 12 month high of $45.92. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. The firm has a market capitalization of $70.38 billion, a PE ratio of 22.05, a P/E/G ratio of 1.29 and a beta of 0.66. The company’s 50 day simple moving average is $38.09 and its 200 day simple moving average is $40.32.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 9th. Investors of record on Friday, November 15th will be paid a $0.3928 dividend. This is a positive change from GSK’s previous quarterly dividend of $0.38. The ex-dividend date is Friday, November 15th. This represents a $1.57 dividend on an annualized basis and a yield of 4.63%. GSK’s dividend payout ratio (DPR) is currently 99.35%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.